PMID- 34830986
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 22
DP  - 2021 Nov 20
TI  - HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients.
LID - 10.3390/cancers13225833 [doi]
LID - 5833
AB  - Several human leukocyte antigen (HLA) alleles are strongly associated with 
      susceptibility to classic Hodgkin lymphoma (cHL), also in subgroups stratified 
      for presence of the Epstein-Barr virus (EBV). We tested the hypothesis that the 
      pressure on cHL tumour cells to lose HLA expression is associated with HLA 
      susceptibility alleles. A meta-analysis was carried out to identify consistent 
      protective and risk HLA alleles in a combined cohort of 839 cHL patients from the 
      Netherlands and the United Kingdom. Tumour cell HLA expression was studied in 338 
      cHL cases from these two cohorts and correlated to the presence of specific 
      susceptibility HLA alleles. Carriers of the HLA-DRB1*07 protective allele 
      frequently lost HLA class II expression in cHL overall. Patients carrying the 
      HLA-DRB1*15/16 (DR2) risk allele retained HLA class II expression in EBV- cHL and 
      patients with the HLA-B*37 risk allele retained HLA class I expression more 
      frequently than non-carriers in EBV+ cHL. The other susceptibility alleles showed 
      no significant differences in expression. Thus, HLA expression by tumour cells is 
      associated with a subset of the protective and risk alleles. This strongly 
      suggests that HLA associations in cHL are related to peptide binding capacities 
      of specific HLA alleles.
FAU - Tan, Geok Wee
AU  - Tan GW
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9700 RB Groningen, The Netherlands.
AD  - Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, 
      National Institutes of Health, Ministry of Health, Shah Alam 40170, Selangor, 
      Malaysia.
FAU - Jiang, Peijia
AU  - Jiang P
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9700 RB Groningen, The Netherlands.
AD  - Department of Laboratory Medicine, Shenyang Huanggu National Defence Hospital, 
      Shenyang 110032, China.
FAU - Nolte, Ilja M
AU  - Nolte IM
AUID- ORCID: 0000-0001-5047-4077
AD  - Department of Epidemiology, University of Groningen, University Medical Center 
      Groningen, 9700 RB Groningen, The Netherlands.
FAU - Kushekhar, Kushi
AU  - Kushekhar K
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9700 RB Groningen, The Netherlands.
FAU - Veenstra, Rianne N
AU  - Veenstra RN
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9700 RB Groningen, The Netherlands.
FAU - Hepkema, Bouke G
AU  - Hepkema BG
AD  - Department of Laboratory Medicine, University of Groningen, University Medical 
      Center Groningen, 9700 RB Groningen, The Netherlands.
FAU - Jarrett, Ruth F
AU  - Jarrett RF
AD  - Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary 
      and Life Sciences, MRC-University of Glasgow Centre for Virus Research, Glasgow 
      G61 1QH, UK.
FAU - van den Berg, Anke
AU  - van den Berg A
AUID- ORCID: 0000-0002-8894-2638
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9700 RB Groningen, The Netherlands.
FAU - Diepstra, Arjan
AU  - Diepstra A
AUID- ORCID: 0000-0001-9239-1050
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9700 RB Groningen, The Netherlands.
LA  - eng
GR  - MC_UU_12014/3/MRC_/Medical Research Council/United Kingdom
GR  - KWF RUG 2014-6698/Dutch Cancer Society/
GR  - NMRR-16-1439-30762/Ministry of Health Malaysia/
PT  - Journal Article
DEP - 20211120
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8616181
OTO - NOTNLM
OT  - EBV
OT  - HLA expression
OT  - cHL
OT  - susceptibility
COIS- The authors declare no conflict of interest.
EDAT- 2021/11/28 06:00
MHDA- 2021/11/28 06:01
PMCR- 2021/11/20
CRDT- 2021/11/27 01:13
PHST- 2021/09/22 00:00 [received]
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/11/17 00:00 [accepted]
PHST- 2021/11/27 01:13 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2021/11/28 06:01 [medline]
PHST- 2021/11/20 00:00 [pmc-release]
AID - cancers13225833 [pii]
AID - cancers-13-05833 [pii]
AID - 10.3390/cancers13225833 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Nov 20;13(22):5833. doi: 10.3390/cancers13225833.